NCT04385836

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Ministry of Health, Saudi Arabia · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Conditions

• Coronavirus

Interventions

Type	Name	Description
DRUG	alpha one antitrypsin inhalation	\- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days

Timeline

• Start date: 2020-06-01
• Primary completion: 2020-09-01
• Completion: 2020-09-01
• First posted: 2020-05-13
• Last updated: 2020-05-13

Locations

1 site across 1 country: Saudi Arabia

Regulatory

• FDA-regulated drug study